SCHEMBL6488069

SCHEMBL6488069

Cc1ccc2[nH]c3c(c2c1)/C(=N/NC(=N)N)CC(C)(C)C3

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.35
MAPT P10636 3/20 0.35
MEN1 O00255 2/20 0.35
HTT P42858 2/20 0.35
KMT2A Q03164 2/20 0.35
GAA P10253 1/20 0.35
SIRT1 Q96EB6 1/20 0.35
BUB1 O43683 3/20 0.34
L3MBTL1 Q9Y468 3/20 0.34
BAZ2B Q9UIF8 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
KDM4E B2RXH2 3/20 0.33
LMNA P02545 2/20 0.32
F2 P00734 1/20 0.32
PTGES O14684 1/20 0.32
HPGD P15428 1/20 0.32
GFER P55789 1/20 0.32
HSD17B10 Q99714 1/20 0.32
RB1 P06400 1/20 0.32
PABPC1 P11940 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488072 1.00 ALDH1A1 (0.35) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL6500149 0.89 MAP2 (0.36) ALDH1A1MAPTMEN1KMT2ABUB1
SCHEMBL6500147 0.89 MAP2 (0.36) ALDH1A1MAPTMEN1KMT2ABUB1
SCHEMBL6487432 0.88 SIRT1 (0.37) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL6487436 0.88 SIRT1 (0.37) ALDH1A1MAPTMEN1KMT2AGAA
SCHEMBL6491884 0.88 SIRT1 (0.37) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL6491882 0.88 SIRT1 (0.37) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL6494583 0.87 MAPT (0.38) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL6494579 0.87 MAPT (0.38) ALDH1A1MAPTMEN1HTTKMT2A
SCHEMBL6490196 0.83 BUB1 (0.37) MAPTKMT2AGAABUB1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6951881-B2 (1-substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2005-10-04 US disclosed
US-20030232843-A1 (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands WYETH (US) 2003-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232843-A1 (1-Substituted-indol-3-yl) alkylidenehydrazinecarboximidamide derivatives as 5-hydroxytryptamine-6 ligands HTR6, HTR5A, HTR1A ALDH1A1 1019/4885MAPT 1293/4885MEN1 3034/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.